苏格兰保健机构建议使用新的杜尚语肌肉萎缩药物AGAMREE,供国家保健服务机构使用。 Scottish health body recommends new Duchenne muscular dystrophy drug AGAMREE® for NHS use.

苏格兰医药联合会(SMC)建议AGAMREE(Vamorolone)在苏格兰国家保健服务系统为四岁以上病人治疗多丘氏肌肉萎缩症(DMD)。 The Scottish Medicines Consortium (SMC) has recommended AGAMREE® (Vamorolone) for treating Duchenne muscular dystrophy (DMD) in NHS Scotland for patients aged four and older. 这是一个重要的步骤,因为AGAMREE是DMD在欧盟、美国和联合王国核准的第一种药物。 This is a significant step, as AGAMREE is the first drug for DMD approved in the EU, US, and UK. 该药物由Santhera制药公司开发,目的是改善肌肉功能,其副作用比目前的治疗少。 The drug, developed by Santhera Pharmaceuticals, aims to improve muscle function with fewer side effects than current treatments.